Detection and monitoring of liver damage
AssigneeThe Cleveland Clinic Foundation
InventorsAriel E. Feldstein, Anna Wieckowska, Nizar Zein
Life of this patent
Estimating the term…
Abstract
A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression.
Claims18
A method of assessing the severity of non-alcoholic fatty liver disease in a subject, the method comprising:
- obtaining a bodily sample from the subject, wherein the bodily sample is selected from the group consisting of blood, plasma, and serum;
- measuring the level of caspase generated cytokeratin-18 fragments in the bodily sample;
- correlating the level of caspase generated cytokeratin-18 fragments with the severity of non-alcoholic fatty liver disease in the subject;
- identifying the subject as having more severe non-alcoholic fatty liver disease the higher the measured level of caspase generated cytokeratin-18 fragments in the bodily sample compared to a predetermined value;
- and
- administering to the subject having non-alcoholic fatty liver disease a therapeutic agent based on the identified severity of the non-alcoholic fatty liver disease.
A method of assessing the degree of non-alcoholic fatty liver disease in a subject, the method comprising:
- obtaining a bodily sample from the subject, wherein the bodily sample is selected from the group consisting of blood, plasma, and serum;
- measuring the level of cytokeratin-18 fragments which are cleaved at aspartic acid residue 396 in the bodily sample;
- correlating the level of cytokeratin-18 fragments which are cleaved at aspartic acid residue 396 with the degree of non-alcoholic fatty liver disease in the subject;
- identifying the subject as having more severe non-alcoholic fatty liver disease the higher the measured level of cytokeratin-18 fragments which are cleaved at aspartic acid residue 396 in the bodily sample compared to a predetermined value;
- and
- administering to the subject having non-alcoholic fatty liver disease a therapeutic agent based on the identified severity of the non-alcoholic fatty liver disease.
A method of assessing the degree of non-alcoholic fatty liver disease in a subject, the method comprising:
- obtaining a bodily sample from the subject, wherein the bodily sample is selected from the group consisting of blood, plasma, and serum;
- measuring the level of caspase generated cytokeratin-18 fragments which are cleaved at aspartic acid residue 396 in the bodily sample;
- correlating the level of caspase generated cytokeratin-18 fragments which are cleaved at aspartic acid residue 396 with the degree of non-alcoholic fatty liver disease in the subject;
- identifying the subject as having more severe non-alcoholic fatty liver disease the higher the measured level of caspase generated cytokeratin-18 fragments which are cleaved at aspartic acid residue 396 in the bodily sample compared to a predetermined value;
- and
- administering to the subject having non-alcoholic fatty liver disease a therapeutic agent based on the identified severity of the non-alcoholic fatty liver disease.
A method of treating non-alcoholic fatty liver disease in a subject, the method comprising:
- identifying the subject as having non-alcoholic fatty liver disease, wherein non-alcoholic fatty liver disease is identified by obtaining a bodily sample selected from the group consisting of blood, plasma, and serum from the subject, measuring the level of caspase generated cyokeratin-18 fragments in the bodily sample, correlating the level of caspase generated cytokeratin-18 fragments with non-alcoholic fatty liver disease in the subject, wherein a subject has non-alcoholic fatty liver disease if the measured level of caspase generated cytokeratin-18 fragments in the bodily sample is higher than a predetermined value;
- and
- administering to the subject identified as having non-alcoholic fatty liver disease a therapeutic agent in an amount effective to treat non-alcoholic fatty liver disease.
Dependencies are inferred from the claim text.